MktsMarkets

Actuate Therapeutics, Inc.
NASDAQ: ACTUKey statistics
ACTU News
Stories mentioning ACTU from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,565 | 2,130 | 2,178 | 2,765 | 3,220 | 3,686 | 3,757 | 4,373 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 5,706 | 4,688 | 5,472 | 5,969 | 6,366 | 6,560 | 5,393 | 5,435 |
| Operating Income (Loss) | (5,706) | (4,688) | (5,472) | (5,969) | (6,366) | (6,560) | (5,393) | (5,435) |
| Interest Income | 85.00 | 139.00 | 70.00 | 25.00 | 54.00 | 117.00 | 81.00 | 9.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (5,626) | (4,555) | (5,407) | (5,949) | (6,317) | (6,446) | (5,971) | (6,572) |
| Earnings Per Share (Basic) | (0.24) | (0.22) | (0.25) | (0.30) | (0.32) | (0.77) | (0.55) | (4.20) |
| Earnings Per Share (Diluted) | (0.24) | (0.22) | (0.25) | (0.30) | (0.32) | (0.77) | (0.55) | (4.20) |
| Weighted Average Shares Outstanding (Basic) | 23,537 | 21,022 | 21,395 | 19,646 | 19,498 | 8,373 | 10,773 | 1,566 |
| Weighted Average Shares Outstanding (Diluted) | 23,537 | 21,022 | 21,395 | 19,646 | 19,498 | 8,373 | 10,773 | 1,566 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ACTU
Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a stock listed on the Nasdaq Stock Market under the ticker symbol ACTU. It last traded at $0.3300 (Nov 9, 2026, 1:24 PM ET), up 1.2% on the day. That gives Actuate Therapeutics a market capitalisation of $18.1M.
Over the past 52 weeks ACTU has traded between $0.3000 and $7.90.
For the quarter ended Mar 31, 2026 it reported a net loss of $5.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$5.6M |
| Dec 31, 2025 | — | -$4.6M |
| Sep 30, 2025 | — | -$5.4M |
| Jun 30, 2025 | — | -$5.9M |
From Actuate Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…